These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 2715807

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Phase II trial of mitoxantrone in head and neck carcinoma.
    Sridhar KS, Hussein AM, Benedetto P, Waldman SM, Feun LG, Savaraj N, Richman SP, Ardalan B, Desai P.
    Am J Clin Oncol; 1991 Aug; 14(4):298-304. PubMed ID: 1650529
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks.
    Siu LL, Oza AM, Eisenhauer EA, Firby PS, Thiessen JJ, Michael M, Wainman N, Manzo J, Feld R, Goldberg RA, Moore MJ.
    J Clin Oncol; 1998 Mar; 16(3):1122-30. PubMed ID: 9508199
    [Abstract] [Full Text] [Related]

  • 28. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer.
    Toussaint C, Izzo J, Spielmann M, Merle S, May-Levin F, Armand JP, Lacombe D, Tursz T, Sunderland M, Chabot GG.
    J Clin Oncol; 1994 Oct; 12(10):2102-12. PubMed ID: 7931480
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy.
    Pusztai L, Holmes FA, Fraschini G, Hortobagyi GN.
    Cancer Chemother Pharmacol; 1999 Oct; 43(1):86-91. PubMed ID: 9923546
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
    Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Blum RH, Zeleniuch-Jacquotte A.
    Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
    [Abstract] [Full Text] [Related]

  • 38. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F, Culine S, Bressolle F, Astre C, Serre MP, Chevillard C, Fabbro M.
    Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
    [Abstract] [Full Text] [Related]

  • 39. Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors.
    Gasparini G, Dal Fior S, Pozza F, Panizzoni GA, Favretto S, Von Hoff DD.
    Invest New Drugs; 1991 Aug; 9(3):245-52. PubMed ID: 1783524
    [Abstract] [Full Text] [Related]

  • 40. Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.
    Young CW, Fanucchi MP, Declan Walsh T, Baltzer L, Yaldaei S, Stevens YW, Gordon C, Tong W, Rifkind RA, Marks PA.
    Cancer Res; 1988 Dec 15; 48(24 Pt 1):7304-9. PubMed ID: 3191501
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.